American global healthcare company, Viatris, has launched a new rapid self-test for qualitative detection of antibodies developed after Covid-19 vaccinations.
The firm is going to market the Covid-19 Neutralising IgG Serological self-test, manufactured by PRIMA Lab SA, in the UK market, which would check presence of
neutralising antibodies after vaccination.
The presence of antibodies indicates that a person has had an immune response to the Covid-19 vaccine, and not that protective immunity has been acquired. The self-test that can be performed easily at home with a small blood sample, delivers results in just 10 minutes and has a recommended retail price of sub £20.
After two doses of the Covid-19 vaccine, the self-test has shown a seroconversion rate of 98.3 per cent for the Pfizer vaccine, 98.5 per cent for the AstraZeneca vaccine and 95.2 per cent for the Moderna vaccine.
It recommended that the test be performed at least 14 days after completing the vaccination cycle.
One in eight people who were hospitalised with Covid-19 between May 2020 and March 2021 were later diagnosed with myocarditis, according to major new research
into the clinical long-term effects of coronavirus.
The largest study of its kind to date was led by the University of Glasgow in collaboration with NHS Greater Glasgow and Clyde (NHS GGC), and followed for one year, in real time, 159 patients after they were hospitalised with Covid-19.
The study also looked at why some patients suffer long-term ill health after hospitalisation with Covid-19. Until now it has been speculated that previous underlying
health conditions may be linked to the severity of post-Covid long-term effects.
However, this new study suggests that it is the severity of the infection itself which is most closely correlated to the severity of a patient's long-Covid symptoms, rather than pre-existing health problems.
Hospitalisation with Covid-19 was found to cause a number of long-term health problems.
Researchers found one in eight patients hospitalised with Covid-19 have heart inflammation, while inflammation across the body and damage to the other organs such as the kidneys was also common.
For the first time, Covid-19 vaccines will be available for purchase from pharmacies in Britain from April 1.
As revealed by The Times, Boots is set to launch a private vaccination service next week to ensure that people "remain ready to respond to this constantly
evolving and unpredictable virus."
Under the NHS national immunization programme (NIP), Covid booster vaccines are only offered to those at high risk, including over-65s or patients with weakened
immune systems.
From April 1, anyone aged 12 or over can get the Pfizer-BioNTech Covid-19 vaccine at 50 Boots stores for £98.95.
While it's highly unlikely for healthier young adults to experience severe Covid-19, getting the single-dose vaccine can protect them from discomforting symptoms
like coughs and sore throats.
A spokesperson for Boots told the publication that their private service is the extension of their existing delivery of Covid-19 vaccinations for the NHS.
The Joint Committee on Vaccination and Immunisation (JCVI) has advised booster vaccination to be offered this autumn (2023) for those at higher risk of severe
Covid-19 in its interim advice to government on the coronavirus (COVID-19) vaccination programme for 2023.
The JCVI also advised that for a smaller group of people, such as those who are older and those who are immunosuppressed, an extra booster vaccine dose in the spring
should also be planned for.
Professor Wei Shen Lim, Chair of Covid-19 vaccination on the JCVI, said: "The Covid-19 vaccination programme continues to reduce severe disease across the population,
while helping to protect the NHS.
That is why we have advised planning for further booster vaccines for persons at higher risk of serious illness through an autumn booster programme later this year.
We will very shortly also provide final advice on a spring booster programme for those at greatest risk."
The routine, twice-weekly asymptomatic Covid-19 testing by pharmacy staff can be paused from the end of August.
The health regulator announced that regular asymptomatic testing for Covid-19 will be paused in all remaining health and care settings from 31 August 2022.
Currently all pharmacy staff test twice-weekly for Covid-19, using a self-administered Lateral Flow Device (LFD) test at home.
"Prevalence of Covid-19 in the community has fallen and remains at a comparatively low level as we emerge from the current Omicron wave. This means that the
likelihood that individuals entering healthcare settings are infectious has also reduced and the relative risk of onward transmission into these settings is lower."
The UK Health Security Agency (UKHSA) and the Office for National Statistics (ONS) will jointly launch a new study to gather data on COVID-19 this winter.
The Winter COVID-19 Infection Study (WCIS) will run from November 2023 to March 2024, involving up to 200,000 participants, UKHSA has said on Monday (October 2).
UKHSA previously commissioned the Coronavirus Infection Survey (CIS), conducted by the ONS in collaboration with scientific study leaders from Oxford University,
analysing more than 11.5 million swab tests and 3 million blood tests from April 2020 to March 2023.
Meanwhile, the Winter CIS study involves conducting up to 32,000 lateral flow tests weekly, providing vital insights into COVID-19 prevalence in the broader
community. The sample will be structured to broadly reflect key population characteristics.
A second Global Covid-19 Summit will be held virtually next month for countries to discuss efforts to end the pandemic and prepare for future health threats, according to a joint statement on Monday (April18).
"The emergence and spread of new variants, like Omicron, have reinforced the need for a strategy aimed at controlling Covid-19 worldwide," the White House said in a news release with the Group of Seven and Group of 20 nations.
The announcement comes amid a surge of Covid-19 cases around the world prompted by easily transmissible variants of the virus.
China's most populous city, Shanghai, is trying to return to normal after a nearly three-week shutdown, which, along with wider China curbs, are taking a toll on the world's No. 2 economy.
The summit will build on efforts and commitments made at the first global summit in September, including getting more people vaccinated, sending tests and treatments to highest-risk populations, expanding protections to health care workers and generating financing for pandemic preparedness, the statement said.
The Department of Health and Social Care (DHSC) announced that free COVID-19 lateral flow tests will be supplied through community pharmacies for at-risk groups.
The service will operate from 6 November for patients aged over 12 years who are at risk of developing severe COVID-19 symptoms.
Community pharmacies that have participated in this new initiative will be paid £4 plus VAT for each box of five lateral flow device test kits provided.
Alastair Buxton, Director of NHS services at Community Pharmacy England said: "This is not going to be a high-volume service, but community pharmacy teams
are well placed to provide LFD test kits to eligible patients with them having made over 25.5 million supplies of COVID-19 LFD test kits in 2021/22.
Representatives from the National Pharmacy Association (NPA) and the Royal Pharmaceutical Society (RPS) presented their preliminary evidence to the Inquiry,
which is examining the impact of the COVID-19 pandemic on healthcare systems in the UK.
The UK COVID-19 Inquiry began on 28 June 2022 to examine the UK's preparedness and response to the pandemic, aiming to draw insights for the future. Its
investigations are organised into modules, gathering evidence from witnesses, experts and core participants through a series of corresponding hearings throughout
each module.
A preliminary Module 3 hearing for its investigation into was held at Dorland House, 121 Westbourne Terrace, London, W2 6BU on Wednesday 10 April at 10.30am.
NPA calls for funding to boost pharmacy resilience
Presenting its evidence before the inquiry, the NPA highlighted the unsung contribution of pharmacies nationwide in combatting COVID-19 and maintaining health
services throughout the pandemic while calling for funding to create greater resilience in community pharmacies.
Prime minister Boris Johnson announced on Wednesday (January 19) that restrictions re-imposed in England last month would be lifted by from next Thursday (January 27).
In the latest development, the government has decided to end the guidance on working from home, asking employers to make adequate arrangements to return safely to work.
From the start of next Thursday, mandatory certification based on vaccines and tests will end, however, organisations can still choose to use the NHS Covid Pass voluntarily.
Besides, the legal mandate to wear face masks will go away from next week.
Making a statement to the House of Commons on Covid-19, he said that infection levels are falling in England mainly because of the country's "extraordinary booster campaign".
He noted more than 36 million Covid-19 booster jabs had been delivered, with over 90 percent of over-60s now given a third dose.
"Our scientists believe it is likely that the Omicron wave has now peaked nationally," Johnson added, while cautioning "the pandemic is not over".
"I encourage everyone across the country to continue with all the cautious behaviours that we know help to keep each everybody safe."
The world has never been in a better position to end the Covid-19 pandemic, the head of the World Health Organization said on September 14, his most optimistic
outlook yet on the years-long health crisis which has killed over six million people.
"We are not there yet. But the end is in sight," WHO Director-General Tedros Adhanom Ghebreyesus told reporters at a virtual press conference.
That was the most upbeat assessment from the UN agency since it declared an international emergency in January 2020 and started describing Covid-19 as a pandemic
three months later.
The virus, which emerged in China in late 2019, has killed nearly 6.5 million people and infected 606 million, roiling global economies and overwhelming healthcare
systems.
The rollout of vaccines and therapies have helped to stem deaths and hospitalisations, and the Omicron variant which emerged late last year causes less severe
disease. Deaths from Covid-19 last week were the lowest since March 2020, the U.N. agency reported.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a second "bivalent" vaccine as a Covid-19 booster.
The updated booster vaccine made by Pfizer/BioNTech, targeting two coronavirus variants, has been approved for use in individuals aged 12 years and above.
In each dose of the booster vaccine, 'Comirnaty bivalent Original/Omicron', half of the vaccine (15 micrograms) targets the original virus strain and the other
half (15 micrograms) targets Omicron (BA.1).
Dr June Raine, MHRA chief executive said: "I am pleased to announce that we now have a second approved vaccine for the UK Autumn booster programme. The clinical
trial of the Pfizer/BioNTech bivalent vaccine showed a strong immune response against the Omicron BA.1 variant as well as the original strain.
Bivalent vaccines are helping us to meet the challenge of an ever-evolving virus, to help protect people against Covid-19 variants. We have in place a comprehensive
safety surveillance strategy for all UK-approved Covid-19 vaccines, and this will include the updated booster we approved today."
The National Institute for Health and Care Excellence (NICE) has issued draft guidance on 'Evusheld' which is not recommended for vulnerable adult with high
risk of severe Covid-19 on Thursday (16 February).
The draft guidance is open for public consultation until 9 March 2023. The committee will consider any comments received at a meeting currently due to take place on
4 April 2023.
It comes after last month's decision by the US drug regulator to withdraw its emergency use authorisation for Evusheld as a preventative treatment for Covid-19,
which said there was insufficient evidence that Evusheld is effective against the dominant variants of Covid-19 in the US.
NICE's independent appraisal committee has reached the same conclusion having considered evidence which shows Evusheld is unlikely to prevent infection with most of
the variants circulating in the UK now and in the near future.
It has also announced that it is developing a new review process to update recommendations on the cost-effectiveness of Covid-19 treatments so they can be made
available more quickly to patients if they show promise against new variants and are found to be cost-effective.
Pfizer's oral Covid-19 therapy will be evaluated as a potential treatment for patients hospitalised with the illness in a major British trial, scientists said on Monday, as cases rise in some parts of the world.
The world's largest randomised study of potential medicines for Covid-19, dubbed the RECOVERY trial, will assess Paxlovid across hospitals in Britain, which has already approved the drug for early-stage treatment.
"Paxlovid is a promising oral antiviral drug but we don't know if it can improve survival of patients with severe Covid-19," said Peter Horby, a professor at the University of Oxford and joint chief investigator of the RECOVERY trial.
The scientists said they aim to mainly find whether Pfizer's Paxlovid reduces the risk of death among patients admitted to hospitals with Covid-19.
The government has accepted the Joint Committee on Vaccination and Immunisation's (JCVI) advice for the autumn 2024 COVID-19 vaccination programme.
According to the JCVI, the following groups will be eligible for vaccination this autumn:
Individuals aged 65 and over
Residents of care homes for older adults
Those aged 6 months and older in clinical risk groups
Minister for Public Health and Prevention, Andrew Gwynne, emphasised the importance of protecting vulnerable populations from COVID-19 and reducing pressure on
the NHS.
He said: "We are committed to protecting those most vulnerable from COVID and have accepted the independent advice from the JCVI for the autumn 2024 vaccination
programme."
"I encourage anyone invited for a vaccine to get one as soon as possible to protect yourself and reduce pressure on the NHS during winter, helping to cut waiting
times and get the health service back on its feet."
Tynor Knee Immobilizer 19 has an extra Patellar strap which is easily flexible and easy to adjust. It provides great relief to the knees after any injury and after operation. It is easily to apply and easy to remove. It properly cushioned the knee and keeps the knee immobilized as well as allows to move anywhere. It has a long shelf life because of its good quality material.
Key Features
Anatomically shaped back splints.
Side splints with relief at knee joint.
Soft and comfortable body.
Additional Features
Lightweight
Anatomically Shaped Back Splints
Side Splints with Relief at Knee Joint
Soft and Comfortable
Perfect Immobilization
Additional Patellar Strapping
Commode chairs are best suited for people who cannot use a regular toilet. The chairs enable patients who have limited mobility due to an accident or any medical condition to use the toilet with ease. The chair allows the patient to use the toilet without causing discomfort to the legs and back. The chair can be used by people who are restricted to a bed or wheelchair. A commode chair is a useful mobility for people of any age who are recovering from injury or surgery. The chair offers a reasonable level of independence to the user; a handy device to be presented to someone who needs it and for whom care. Commode Wheelchairs which are specially designed for aged and physically challenged people. These wheelchairs can be used for indoor toilet purposes. Fabricated using quality raw material, these wheelchairs are suitable for domestic and hospital purpose.
There are two types for handicapped and disability product like Commode Wheelchair-
Commode Wheelchair Rainbow 6
Commode Wheelchair Rainbow 7
Commode Wheelchair Rainbow 6:
Karma commode wheelchair rainbow 6 comes with lot of exiting features for elderly or physically challenged person who want commode in wheelchair. Karma Rainbow 6 has single seat with center cut commode having cushion cover on top and removable pan or plastic commode seat with pot.
Commode Wheelchair Rainbow 6 Features:
Frame Material : M.S.Chrome Plated
Single Seat with center cut commode
Both Option Available In Single Seat
Plastic Commode Seat With Pot.
Cushioned Top Cover
Square Pan Commode Pan
Removable Pan
Commode Wheelchair Rainbow 6 Measurements:
Frame Style : Foldable
Open Position Wheel To Wheel Width In : 26" (Inches)
Seat Width : 18" (Inches)
Total Width in Closing Position : 11" (Inches)
Rear Wheel Size : 24" (Inches)
Front Wheel Size : 8" (Inches)
Seat to Floor Height : 19" (Inches)
Seat Depth : 18" (Inches)
Total Height : 34" (Inches)
Max User Weight Capacity : 110 (kgs)
Community pharmacy is at the heart of one of the most ambitious clinical trials ever undertaken by the UK's primary care network, says senior academic pharmacist
Professor Mahendra Patel.
The PANORAMIC trial has been designed to rapidly evaluate several antiviral treatments over time that could help people at high risk of Covid-19 recover sooner,
prevent the need for hospital admission and so ease the burden on the NHS.
The Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC) is a national priority trial led by Oxford University's
Primary Care Clinical Trials Unit.
Lead investigators say the study will enable early and rapid testing of novel antiviral agents and help repurpose existing drugs against Covid-19. As soon as the trial is set up for delivery, it will be open to eligible participants from across the UK.
Prof Patel, a key member of the trial's core team, said: "I'm really excited with this news and also by the prospect that there is a huge potential for pharmacy teams to help play a vital role in supporting this highly ambitious trial, as they have with the PRINCIPLE trial, now the world's largest community based clinical trial for Covid19."
The government has launched a new campaign over social media and radio today (January 10) to encourage pregnant women to take their first, second and third dose of Covid-19 vaccine.
Joined by experts at the Royal College of Obstetricians and Gynaecologists (RCOG) and the Royal College of Midwives (RCM), the campaign highlights the risks of the infection and benefits of vaccination.
According to the latest data from the UK Health Security Agency (UKHSA), Covid-19 vaccinations are safe for pregnant women.
Department of Health and Social Care (DHSC) chief scientific adviser professor Lucy Chappell, said: "We have extensive evidence now to show that the vaccines are safe and that the risks posed by Covid-19 are far greater," calling upon pregnant women who have yet to have their jabs.
The campaign will also run testimonies of pregnant women who have had their jabs.
A new study has revealed that the risk of death from COVID-19 decreases significantly after vaccination, but this protection diminishes after six months,
providing evidence for continued booster doses.
Researchers from the UK Health Security Agency (UKHSA), who analysed more than 10 million cases of COVID-19 in adults in England between May 2020 and February
2022, found a clear association between vaccination and reduced mortality.
But they also highlighted a crucial timeframe - within six months of the last vaccine dose - when Case Fatality Risk (CFR) - the proportion of cases that resulted
in death - was consistently at its lowest across all age groups. After this, the protective benefit of the vaccine began to wane and CFR increased.